Saturday, June 1, 2024, Chicago, Illinois, 6:45 AM – 7:45 AM Central Time (7:45 AM – 8:45 AM Eastern Time)

Breakfast with the Investigators: Current and Emerging Role of Antibody-Drug Conjugates in the Treatment of Lung Cancer

A CME Hybrid Symposium Held in Conjunction with the 2024 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois
Phone: (312) 922-4400

Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast
6:45 AM – 7:45 AM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Rebecca S Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Thoracic Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Luis Paz-Ares, MD, PhD
Chair of the Medical Oncology Department
at the Hospital Universitario 12 de Octubre
Associate Professor at the Universidad Complutense
Head of the Lung Cancer Unit at the National Oncology Research Center
Madrid, Spain

Moderator
Jacob Sands, MD
Physician
Dana-Farber Cancer Institute
Assistant Professor
Harvard Medical School
Boston, Massachusetts



This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, and Daiichi Sankyo Inc.
Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast
6:45 AM – 7:45 AM — Educational Meeting

Discussion Topics

  • Integration of Antibody-Drug Conjugates (ADCs) into the Care of Patients with Non-Small Cell Lung Cancer (NSCLC) and HER2 Alterations
  • Emerging Role of TROP2-Targeted ADCs for NSCLC
  • Other Promising Targets for ADCs in Lung Cancer

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Understand the cellular targets, structural components and mechanisms of action of available and investigational antibody-drug conjugates (ADCs) with documented activity in patients with lung cancer.
  • Evaluate available efficacy and safety findings with HER2-directed ADCs for patients with metastatic non-small cell lung cancer (NSCLC), and assess the optimal placement of this form of therapy in the current treatment algorithm.
  • Consider the biological rationale for the development of ADCs targeting TROP2 for NSCLC, and recognize available efficacy and safety findings with these agents in patients with relapsed/refractory disease.
  • Appreciate the incidence of HER3 overexpression in patients with NSCLC, and develop an understanding of the rationale for and available data with HER3-directed ADCs for metastatic NSCLC with an EGFR mutation.
  • Acknowledge the potential utility of c-Met as a therapeutic target in NSCLC, and recollect available and emerging efficacy and safety findings with novel c-Met-directed ADCs for patients with previously treated disease.
  • Recognize the spectrum, frequency, severity and optimal management of toxicities associated with novel ADCs with activity in lung cancer, and apply this information to facilitate the safe and effective use of these agents.
  • Recall the design of ongoing clinical trials evaluating novel ADCs or combination strategies with these agents for lung cancer, and counsel appropriate patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Heist — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Biohaven, Claim Therapeutics, Daiichi Sankyo Inc, Lilly, Merck, Novartis, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Agios Pharmaceuticals Inc, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Erasca, Lilly, Mirati Therapeutics Inc, Mythic Therapeutics, Novartis, Turning Point Therapeutics Inc. Dr Paz-Ares — Advisory Committees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, GSK, Janssen Biotech Inc, Lilly, Merck, Mirati Therapeutics Inc, MSD, Novartis, Pfizer Inc, PharmaMar, Roche Laboratories Inc, Sanofi, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc; Boards of Directors: Altum Sequencing, STAb Therapeutics; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Lilly, Mirati Therapeutics Inc, MSD, PharmaMar, Sanofi.

MODERATOR — Dr Sands — Advisory Committee: Curadev; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Medtronic Inc, Pfizer Inc, PharmaMar, Sanofi; Contracted Research: Amgen Inc, Harpoon Therapeutics; Data and Safety Monitoring Board/Committee: Johnson & Johnson Pharmaceuticals.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, and Daiichi Sankyo Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Grand Ballroom (Level 2)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of lung cancer.

There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2024 ASCO Annual Meeting.

IN-PERSON Registration
Thank you for your interest in our CME program taking place in Chicago. At this time online registration to attend this event in person is closed. SEATS ARE STILL AVAILABLE FOR THE PROGRAM AND WILL BE OFFERED ON A FIRST COME, FIRST SERVED BASIS. Our onsite registration desk will be open at 6:15 AM central time on Saturday, June 1st. If you are interested in attending, please visit our registration desk outside the Grand Ballroom (Level 2) of the Hilton Chicago hotel (720 South Michigan Avenue). ASCO offers complimentary shuttle service from the McCormick Place Convention Center to this hotel. Information on the shuttle service is available on the 2024 ASCO Annual Meeting website.

Please note, onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.
LIVE WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.